DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
Status:
Terminated
Trial end date:
2019-01-28
Target enrollment:
Participant gender:
Summary
Determine the efficacy, in terms of time to nausea (inclination to vomit), of DPI-386 Nasal
Gel as compared to the current standard of care (TDS) and placebo nasal gel. • Describe the
pharmacokinetics (PK) of a multi-dose schedule of DPI-386 Nasal Gel (0.2 mg twice a day for
six consecutive days) as compared to the current standard of care (TDS). Determine the safety
of a multi-dose schedule of DPI-386 Nasal Gel with an emphasis on cognitive adverse events as
compared to the current standard of care (TDS) and placebo nasal gel. Determine how alertness
is affected by administration of DPI-386 Nasal Gel, as compared to the current standard of
care (TDS) and placebo nasal gel.